10:43 AM
 | 
Jan 18, 2019
 |  BC Week In Review  |  Company News  |  Deals

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS).

ZappRx founder and CEO Zoë Barry did not disclose financial details.

Bayer markets sGC activator Adempas riociguat with partner Merck & Co. Inc. (NYSE:MRK) to treat pulmonary hypertension, and recombinant...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >